All serious adverse events · children
Rotarix leads to lower all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.85 [0.76, 0.95]
9 studies · 77069 participants
High
RR 0.9 [0.77, 1.05]
10 studies · 7674 participants
High
RR 0.89 [0.72, 1.1]
12 studies · 18971 participants
High
Serious adverse events: intussusception · children
Rotarix showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.72 [0.39, 1.32]
6 studies · 75540 participants
Low
RR 1.49 [0.06, 36.63]
5 studies · 17068 participants
Low
RR 1.42 [0.52, 3.87]
10 studies · 20773 participants
Low
Severe cases of rotavirus diarrhoea · children
RotaTeq leads to lower severe cases of rotavirus diarrhoea compared with placebo (high certainty).
6 findings from 1 review
Show 3 more findings
RR 0.21 [0.11, 0.41]
1 study · 3863 participants
Low
RR 0.43 [0.29, 0.64]
2 studies · 6775 participants
High
RR 0.56 [0.41, 0.77]
2 studies · 6744 participants
High
Severe cases of all‐cause diarrhoea · children
The review found no eligible studies for this question.
6 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Show 3 more findings
All‐cause death · children
RotaTeq showed no clear difference in all‐cause death compared with placebo (low certainty).
3 findings from 1 review
RR 1.24 [0.69, 2.22]
6 studies · 72654 participants
Low
RR 0.33 [0.01, 8.18]
2 studies · 4088 participants
Very low
RR 0.91 [0.68, 1.23]
3 studies · 7706 participants
Moderate
All serious adverse events · children
RotaTeq showed no clear difference in all serious adverse events compared with placebo (high certainty).
3 findings from 1 review
RR 0.92 [0.84, 1.01]
5 studies · 70690 participants
High
RR 0.66 [0.14, 3.17]
2 studies · 4082 participants
Very low
RR 0.99 [0.72, 1.36]
4 studies · 7730 participants
Moderate
Serious adverse events: intussusception · children
RotaTeq showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
3 findings from 1 review
RR 0.69 [0.35, 1.38]
9 studies · 73925 participants
Low
RR 5.01 [0.24, 104.29]
2 studies · 4082 participants
Very low
RR 0.33 [0.01, 8.16]
2 studies · 7488 participants
Low
Severe cases of rotavirus diarrhoea · children
Rotasiil leads to lower severe cases of rotavirus diarrhoea compared with placebo (high certainty).
2 findings from 1 review
Severe cases of all‐cause diarrhoea · children
Rotasiil showed no clear difference in severe cases of all‐cause diarrhoea compared with placebo (high certainty).
2 findings from 1 review
All‐cause death · children
Rotasiil showed no clear difference in all‐cause death compared with placebo (moderate certainty).
1 finding from 1 review
All serious adverse events · children
Rotasiil showed no clear difference in all serious adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
Rotasiil showed no clear difference in serious adverse events: intussusception compared with placebo (low certainty).
1 finding from 1 review
Severe cases of rotavirus diarrhoea · children
Rotavac probably leads to lower severe cases of rotavirus diarrhoea compared with placebo (moderate certainty).
2 findings from 1 review
Severe cases of all‐cause diarrhoea · children
Rotavac probably leads to lower severe cases of all‐cause diarrhoea compared with placebo (moderate certainty).
2 findings from 1 review
All‐cause death · children
It is very uncertain whether rotavac changes all‐cause death compared with placebo (very low certainty).
1 finding from 1 review
All serious adverse events · children
Rotavac showed no clear difference in all serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events: intussusception · children
It is very uncertain whether rotavac changes serious adverse events: intussusception compared with placebo (very low certainty).
1 finding from 1 review
Parasitaemia prevalence · People of all ages living in an area with moderate to high endemicity of P falciparum malaria (≥ 10% prevalence)
MDA showed no clear difference in parasitaemia prevalence compared with no MDA (low certainty).
1 finding from 1 review
Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P falciparum malaria ( < 10% prevalence)
It is very uncertain whether MDA changes parasitaemia prevalence compared with no MDA (very low certainty).
6 findings from 1 review
Show 3 more findings
Parasitaemia prevalence · People of all ages living in an area with very low to low endemicity of P vivax malaria (< 10% prevalence)
MDA may leads to lower parasitaemia prevalence compared with no MDA (low certainty).
6 findings from 1 review
Show 3 more findings